{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-279097","form_type":"8-K","ticker":"AVIR","cik":"0001593899","company_name":"Atea Pharmaceuticals, Inc.","filed_at":"2022-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.335549+00:00","generated_at":"2026-06-22T05:27:51.093276+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Atea Pharma reports Q3 net loss $8.1M; cash $665M; SUNRISE-3 enrollment imminent","bullets":["Net loss of $8.1M ($0.10 per share) vs net loss of $28.2M in Q3 2021.","Cash and marketable securities $665.0M at Sept 30, 2022, down from $764.4M at Dec 31, 2021.","R&D expenses fell to $4.9M from $43.0M, aided by a $14.5M credit from Roche cost share close-out.","SUNRISE-3 Phase 3 trial for bemnifosbuvir in high-risk COVID-19 patients expected to start enrollment before year-end 2022.","AT-752 human challenge study and DEFEND-2 first cohort completion expected around year-end; HCV trial submission also anticipated."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-279097","json":"https://secwatch.observer/filing/0001193125-22-279097.json","markdown":"https://secwatch.observer/filing/0001193125-22-279097.md","text":"https://secwatch.observer/filing/0001193125-22-279097.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1593899/000119312522279097/0001193125-22-279097-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1593899/000119312522279097/d411939d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T05:27:51.093276+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"778d9c5c011474296ff27a547880b09c6c4ac11c","claim":"Atea Pharmaceuticals, Inc. reported financial results for third quarter ended September 30, 2022.","evidence_excerpt":"Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1593899/000119312522279097/0001193125-22-279097-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}